Expand PLX Menu
PLX MENU

PLX Latest Press Releases

-- March 18, 2026 --

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results PRNewswire 6:50 AM

-- March 11, 2026 --

Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 PRNewswire 6:50 AM

-- March 9, 2026 --

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio (pegunigalsidase alfa) ? Globe Newswire 8:30 AM
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio (pegunigalsidase alfa) Globe Newswire 6:00 AM

-- March 4, 2026 --

Ellomay Capital Announces Changes in its Principal Shareholders and Board Composition Globe Newswire 4:32 PM

-- January 30, 2026 --

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio (pegunigalsidase alfa) ? in the EU Globe Newswire 9:47 AM
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio (pegunigalsidase alfa) in the EU Globe Newswire 9:47 AM

-- January 5, 2026 --

Protalix BioTherapeutics Letter to Stockholders PRNewswire 6:50 AM

-- December 17, 2025 --

Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement PRNewswire 6:50 AM

-- November 13, 2025 --

Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results PRNewswire 6:50 AM

-- November 6, 2025 --

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 PRNewswire 6:50 AM

-- November 5, 2025 --

PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm Globe Newswire 10:50 AM

-- November 3, 2025 --

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU Globe Newswire 4:30 PM

-- October 31, 2025 --

PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm Business Wire 8:31 PM

-- October 28, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX PRNewswire 10:00 AM
Market Data Delayed 15 Minutes